|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield
Connecticut
06877
U.S.A.
Phone:
203-798-9988
Fax:
n/a
|
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
Value Through Innovation
Our vision of Value through Innovation (VTI) guides our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. It also helps us foster value creation throughout our company and to look to the future with constantly renewed commitment and ambition.
Our Lead & Learn principles outline ways in which we can build on our culture of working together to realize and deliver Value through Innovation. These principles encourage us to take risks, ask questions, and seize opportunities in an environment of shared leadership and learning.
Our Success Depends on our People
For more than 125 years, the commitment, innovative-thinking and creative power of our people has made Boehringer Ingelheim one of the fastest growing pharmaceutical companies and an employer of choice. Our workplace reflects our distinctive and innovative culture, built on a foundation of mutual respect and fairness.
We have high expectations and require employees at all levels of the organization to take initiative, stay connected, grow together and achieve outstanding results. To enable this high performance we provide opportunities for personal growth, a collaborative and inclusive work environment and exceptional employee benefits and we reward high achievement with recognition, opportunities and competitive pay.
Driven by a Different Philosophy
We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to create a healthy working environment, meaningful work, diversity, mobility, networking and work-life balance.
In a world where business is too often driven by short-term financial goals, Boehringer Ingelheim is truly a company with a different philosophy. As one of the fastest growing pharmaceutical companies in the world, our focus is on helping patients, serving our customers and improving the quality of life for the millions of people who rely on us. Simply put, we remain committed to doing the right thing – for our customers, our communities, our employees and everyone we serve.
Because our products enhance millions of lives, our employees experience the satisfaction of doing important work. Their achievements bring them recognition, and opportunities for career growth. We invite you to join us in improving lives worldwide.
Email:
Ownership:
Private
Web Site:
Boehringer Ingelheim Pharmaceuticals, Inc.
Employees:
More than 9,000 Employees in the US; 42,000 Worldwide
Symbol:
|
|
|
Company News |
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Transition to Propellant-Free Combivent® Respimat® (Ipratropium Bromide and Albuterol) Inhalation Spray Nears Completion
5/17/2013 9:32:24 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. to Present 17 Abstracts at the Annual American Thoracic Society International Conference
5/17/2013 7:11:15 AM
More...
|
American Society of Clinical Oncology 2013: Boehringer Ingelheim Pharmaceuticals, Inc. to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5/16/2013 9:55:28 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5/16/2013 7:00:19 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (LLY) Launch Educational Campaign About Emerging Science in Type 2 Diabetes
5/2/2013 10:07:13 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc.'s Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial
4/23/2013 10:26:21 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
4/8/2013 7:21:57 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated With Faldaprevir
3/4/2013 10:37:27 AM
More...
|
Pharmaceutical Leader Boehringer Ingelheim Pharmaceuticals, Inc. Selects Republica as Cross-Cultural Marketing Agency
2/22/2013 8:47:41 AM
More...
|
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Study Results Published in The New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
2/21/2013 9:30:17 AM
More...
|
|
|
|
 |
|
|
|
|
|
|